Abiopharma

🔍 Rhodes Jennifer J (Executive)

Company: ACADIA PHARMACEUTICALS INC (ACAD)

Report Date: 2026-03-24

Detailed Transactions and Holdings:

• Acquired 7,515 shares of Common Stock (Direct)
  Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,124.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,844 shares of Common Stock at $21.47 per share (Direct)
  Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 11,280.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,515 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 22,547.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
• F3: The restricted stock units vest in four equal annual installments beginning March 24, 2026.